Aytu Biopharma (AYTU) Cash & Equivalents Growth (3y) (2017 - 2026)
Powered by 
Analysis
Aytu Biopharma (AYTU) Cash & Equivalents Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -1.21% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -9.15% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 6.56% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -11.22% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -28.16% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -5.35% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 8.35% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 19.10% |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn | 11.68% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 11.68% |
| Dec 31, 2025 | 15.47% |
| Sep 30, 2025 | 11.07% |
| Jun 30, 2025 | 16.93% |
| Mar 31, 2025 | -13.02% |
| Dec 31, 2024 | -16.69% |
| Sep 30, 2024 | -20.69% |
| Jun 30, 2024 | -26.26% |
| Dec 31, 2023 | -31.97% |
| Sep 30, 2023 | -19.25% |
| Jun 30, 2023 | -21.81% |
| Mar 31, 2023 | -32.47% |
| Dec 31, 2022 | 54.78% |
| Sep 30, 2022 | 50.29% |
| Jun 30, 2022 | 20.57% |
| Mar 31, 2022 | 23.53% |
| Dec 31, 2021 | 25.60% |
| Sep 30, 2021 | 116.63% |
| Jun 30, 2021 | 92.34% |
| Dec 31, 2020 | 151.31% |